Ligand Raises $700M Via 0% Convertible Notes, Adds Note Hedges and $524.34 Strike Warrants
Ligand Pharmaceuticals has successfully completed a $700 million private offering of 0.00% Convertible Senior Notes due 2031 to enhance its liquidity and financial flexibility. To mitigate dilution, the company entered into convertible note hedge transactions covering approximately 2.09 million shares and sold warrants with a $524.34 strike price, covering about 4.19 million shares, to help offset hedging costs. The notes are initially convertible at $334.27 per share and are senior unsecured.
Ligand (NASDAQ: LGND) sets $550M convert deal and $75M buyback
Ligand Pharmaceuticals announced a private offering of $550 million in convertible senior notes due 2031, with an option for an additional $82.5 million. The company plans to use part of the proceeds for convertible note hedge and warrant transactions, repurchase up to $75 million of its common stock, and fund general corporate purposes, including the acquisition of Xoma Royalty Corporation. Concurrently, a Fourth Amendment to its Credit Agreement was made, adjusting minimum Consolidated EBITDA requirements to facilitate this offering.
JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo
JALAA Equities LP reported the sale of 500 common shares of Ligand Pharmaceuticals (LGND) on June 10, 2026, for $124,980.42. The SEC filing also indicated 4,500 common shares associated with Wells Fargo Clearing Services, originally purchased on April 28, 2005. This Rule 144 notice details the disposition and linked shares, clarifying that the 500 shares sold by JALAA Equities LP were distinct from the Wells Fargo-linked shares.
Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, a non-binding advisory resolution on executive compensation, and an amendment and restatement of the Company’s 2002 Stock Incentive Plan. The approvals demonstrate strong investor support for the company's governance and compensation strategies.
Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants
Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards comprising 836 restricted stock units (RSUs) and 2,938 non-qualified stock options with a strike price of $237.00 per share. These awards, granted on June 5, 2026, fully vest on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date. Following these compensation-related grants, Sabba directly holds 33,629 shares of Ligand common stock, in addition to the newly awarded options.
LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition
Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. Additionally, 182 shares were withheld to cover tax liabilities associated with the RSU settlement, a non-market disposition.
Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants
Ligand Pharmaceuticals director Jason Haas received 836 restricted stock units (RSUs) and a non-qualified stock option for 2,938 shares as part of his board compensation on June 5, 2026. The RSUs and options fully vest on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date. Following these grants, Haas directly holds 7,442 shares of common stock, and the stock option has an exercise price of $237 per share and expires on June 5, 2036.
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit from a poor investment, as Reardon maintains significant direct and option holdings. The article highlights Ligand's strong one-year return and growing royalty revenue, advising investors to consider "The Motley Fool Stock Advisor" for top stock picks, though Ligand was not among them.
Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and also impacted other heavily shorted stocks, caused significant outrage among retail investors and led to calls for Congressional hearings. The law firm is seeking to represent investors who suffered losses due to these limitations imposed by brokerage firms.
LGND - Ligand Pharmaceuticals Inc Stock Price and Quote
This page provides comprehensive financial data and news for Ligand Pharmaceuticals Inc. (LGND), including its stock price, key financial metrics, analyst ratings, and recent corporate announcements. It also details insider trading activities, offering a snapshot of the company's performance and significant events.
Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis
Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an uplift in its 2026 revenue and EPS outlook. Despite being considered undervalued by analysts, current valuation may already reflect much of the anticipated growth, with key risks including regulatory uncertainty and potential exclusivity loss on some royalty streams.
LGND: XOMA Buy Adds 100+ Assets
Ligand Pharmaceuticals (NASDAQ: LGND) announced the acquisition of XOMA Royalty Corporation (NASDAQ: XOMA) for $739 million, adding over 100 assets to its portfolio. The all-cash transaction, expected to close in Q3 2026, is projected to be immediately accretive to Ligand's earnings, increasing 2026 revenue estimates by $25 million and EPS by $0.50. The acquisition also brings tax benefits and complements recent FDA approvals for Filspari and Tzield, reinforcing Ligand's strategy of building a diversified royalty portfolio.
Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company
Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary of Ligand. The amendment aims to streamline the acquisition of XOMA Royalty.
Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company
Ligand Pharmaceuticals (LGND) has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation as a party, formalizing a Nevada holding company reorganization. This amendment clarifies the legal structure of the previously announced acquisition, with XOMA Royalty Holdings surviving as a wholly-owned subsidiary of Ligand. The transaction remains subject to regulatory approvals and XOMA Royalty stockholder approval.
Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND
Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a "Moderate Buy" consensus rating, the company reported mixed quarterly results with EPS and revenue missing estimates. Insider selling by Stephen L. Sabba and Andrew Reardon also occurred within the last 90 days.
Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed
Ligand Pharmaceuticals reported strong Q1 2026 results with royalty revenue increasing 56% year-over-year to $43.0 million, primarily driven by products like Filspari, Ohtuvayre, and Capvaxive. Despite a GAAP net loss of $13.3 million due to non-cash items, adjusted net income rose 30% to $34.6 million. The company reaffirmed its full-year 2026 financial guidance, anticipating $225–$250 million in royalty revenue, and highlighted progress on the pending acquisition of XOMA Royalty.
UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND
UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms raising price targets and maintaining buy ratings despite the company missing Q1 EPS and revenue estimates, though revenue still grew year-over-year. Insider selling has also been noted, with the CFO and a director reducing their holdings.
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination
Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months and is currently considered undervalued by analysts, trading at $220.48 against a narrative fair value of $246.70. The company's valuation is heavily influenced by its expanding high-margin royalty portfolio, although its P/E ratio of 28.8x is higher than the industry average, suggesting less room for error if expectations are not met.
XOMA Royalty to Be Acquired by Ligand in $39-Per-Share Cash Deal Plus CVRs
XOMA Royalty has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus contingent value rights (CVRs) from RemainCo LLC. The deal awaits HSR clearance and stockholder approval, with key XOMA stakeholders, including BVF Partners, already committed to supporting the merger, covering about 47% of outstanding shares. A $40 million termination fee for XOMA is part of the merger agreement under specific conditions.
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed has received a $15 million investment from Ligand Pharmaceuticals, fulfilling a scheduled tranche of their royalty-based financing agreement and bringing the total capital from Ligand to $40 million. This funding, along with an additional $20 million from Medtronic, will support the continued execution of Orchestra BioMed's pivotal trials for its AVIM Therapy and Virtue Sirolimus AngioInfusion Balloon. Both companies expressed confidence in the progress and potential of these cardiovascular therapies.
Ligand to Participate in May Investor Conferences
Ligand Pharmaceuticals announced its senior management team will participate in several investor conferences throughout May 2026, including the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, CJS Securities Spring 1x1 Conference, H.C. Wainwright BioConnect Investor Conference, RBC Capital Markets Global Healthcare Conference, Craig-Hallum Institutional Investor Conference, and Benchmark Healthcare House Call Conference. During these events, management will engage in fireside chats and host one-on-one meetings with investors and attendees. Ligand, a leading royalty aggregator, funds biopharmaceutical development programs in exchange for economic interests, boasting a diverse portfolio of over 100 assets.
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the sales of XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. The firm is examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders, particularly regarding whether insiders unfairly benefit from these deals. Shareholders are encouraged to contact the firm to discuss their rights and options.
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)
Vanguard Portfolio Management has reported a 5.56% beneficial ownership stake in Ligand Pharmaceuticals Inc. (NASDAQ: LGND), holding 1,109,154 shares. The Schedule 13G filing indicates sole voting power over 8,887 shares and sole dispositive power over all 1,109,154 shares. This disclosure, signed by Ashley Grim on May 1, 2026, highlights Vanguard's significant but passive investment in the biotechnology company.
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake
Vanguard Capital Management has filed a Schedule 13G on Ligand Pharmaceuticals Inc. (LGND), reporting a beneficial ownership of 997,637 shares, which represents a 5% stake in the company's common stock as of March 31, 2026. The filing indicates Vanguard possesses sole dispositive power over all these shares and sole voting power over 149,548 shares. This disclosure provides transparency regarding Vanguard's significant investment in Ligand.
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event
Ligand Pharmaceuticals Inc. (LGND) filed an 8-K report announcing the termination of the TR-Beta Program under its Master License Agreement with Viking Therapeutics, Inc., effective May 4, 2026. Ligand asserts that Viking materially breached its obligation to use commercially reasonable efforts for the program's development and commercialization. Viking disputes this termination, while Ligand intends to vigorously enforce its rights.
B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND
B. Metzler seel. Sohn & Co. AG has invested $1.30 million in Ligand Pharmaceuticals (NASDAQ:LGND) by purchasing 6,879 shares in Q4, bringing institutional ownership to approximately 91.28%. Despite this, company insiders, including the CFO and a director, have recently sold shares totaling about $6.39 million. Ligand Pharmaceuticals reported strong quarterly earnings, beating estimates with $2.02 EPS and $59.67 million in revenue, and has issued a positive FY2026 EPS guidance of $8.00–$9.00.
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs
Ligand Pharmaceuticals has entered into a definitive merger agreement to acquire XOMA Royalty for $39.00 per share in cash, along with contingent value rights (CVRs) tied to a CVR Trust. The deal is contingent on XOMA Royalty stockholder approval, HSR clearance, and a holding company reorganization and CVR spin. Ligand has also secured voting and support agreements from holders representing approximately 47% of XOMA Royalty's common shares to facilitate the transaction.
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal
Ligand Pharmaceuticals announced its agreement to acquire XOMA Royalty Corporation for $739 million in cash, equating to $39.00 per share plus a contingent value right tied to Janssen litigation proceeds. This acquisition will significantly expand Ligand's biopharma royalty portfolio by adding seven commercial products and over 100 development-stage assets. Ligand expects the deal to be immediately accretive, raising its 2026 adjusted EPS guidance to $8.50–$9.50 and projecting an additional $1.50 per share to adjusted EPS in 2027.
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals has announced its intent to acquire XOMA Royalty for $39.00 per share, an equity value of approximately $739 million, plus a non-transferable CVR tied to ongoing litigation. This acquisition is set to expand Ligand's royalty portfolio to over 200 assets, adding seven marketed products, and is expected to close in Q3 2026. Ligand has also raised its 2026 financial guidance, anticipating the transaction to be accretive to adjusted EPS by $1.50 in 2027.
Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND
Impax Asset Management Group plc reduced its stake in Ligand Pharmaceuticals Incorporated by 17.5%, selling 35,000 shares and now holding 165,208 shares valued at approximately $31.24 million. Despite this sale, Ligand Pharmaceuticals reported strong quarterly results with EPS of $2.02 and revenue of $59.67 million, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $247.29. Insider selling was also noted, with executives selling shares totaling over $1.6 million, while institutional investors collectively own 91.28% of the company's stock.
Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND
Assetmark Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 4,933.3%, now owning 6,191 shares valued at approximately $1.17 million. Analysts maintain a "Moderate Buy" consensus with a price target of $247.29, following strong quarterly earnings where Ligand reported $2.02 EPS (beating estimates by $0.56) and revenue of $59.67 million, up 39.5% year-over-year. The company also provided a positive FY2026 EPS guidance of $8.00–$9.00.
Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan
Ligand Pharmaceuticals (LGND) is seeking stockholder approval for an expanded equity plan at its June 5, 2026, annual meeting, following a strong financial performance in 2025. The company reported a 48% increase in royalty revenue and a 42% rise in adjusted EPS, driven by its royalty-focused biopharmaceutical model and successful partner product launches. The proposed changes to the 2002 Stock Incentive Plan include increasing the share reserve by 600,000 shares, removing the fungible pool formula, and updating director compensation limits, aimed at maintaining competitive employee and director incentives.
LGND Financials: Revenue Breakdown, Margins & Competitor Comparison
The article analyzes Ligand Pharmaceuticals Inc (LGND) financials, highlighting its revenue breakdown, profitability margins, and competitive position. Kyprolis is LGND's largest revenue contributor, accounting for 18.5% of total sales. The company demonstrates strong profitability with an 81.42% gross margin and a 75.06% net margin, outperforming competitors like AMRX in efficiency.
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc has reduced its stake in Ligand Pharmaceuticals Incorporated by 37.1% during the fourth quarter, selling over 70,000 shares. Despite this reduction and recent insider selling, Ligand Pharmaceuticals reported strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with a target price of $245.86. Institutional investors collectively own a significant portion of the company's stock at 91.28%.
Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares
John L. LaMattina, a director at Ligand Pharmaceuticals (NASDAQ: LGND), exercised non-qualified stock options for 2,161 shares at $114.15 per share and subsequently sold all those shares for $200.76 per share in an open-market transaction. Following these transactions on March 6, 2026, LaMattina directly holds 30,724 shares of Ligand common stock, with the option position now fully exercised. The net sale amounted to 2,161 shares, valued at $433,842.
LGND Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Ligand Pharmaceuticals Inc (LGND), indicating a "Sell" consensus based on various indicators. It details the stock's performance relative to moving averages, its RSI, MACD readings, and key support and resistance levels. The analysis aggregates 10 technical signals, showing more sell indicators than buy indicators as of April 2, 2026.
Ligand Pharma CLO Sells $1.03M in Stock | Transaction Details & Company Background - News and Statistics
Ligand Pharmaceuticals Inc.'s Chief Legal Officer, Andrew Reardon, sold approximately $1.03 million in company stock after exercising options for 5,000 shares. This transaction reduced his direct holdings by nearly 12%, though he still retains substantial unexercised employee stock options. The sale occurred at a weighted average price of $206.35 per share, following Ligand's strong one-year stock performance exceeding 80%.
Vanguard (LGND) reports 0 shares after internal realignment (03/27/2026)
The Vanguard Group filed an amended Schedule 13G/A report for Ligand Pharmaceuticals Inc. (LGND), stating it now beneficially owns 0 shares and 0% of the common stock. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. This filing reflects an administrative change rather than a sale or purchase of stock.
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Ligand Pharmaceuticals announced the appointment of Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, expanding its team. Lauren Hay is also transitioning to Vice President of Portfolio Strategy and Investments. These changes aim to strengthen Ligand's strategic growth, capitalize on new investment opportunities, and enhance long-term value creation by focusing on royalty financing and optimizing existing portfolio assets.
Ligand Pharmaceuticals Unveils Two New VPs of Investments, Business Development
Ligand Pharmaceuticals has appointed Peter Renehan, MD, and Lee Brown as new Vice Presidents of Investments and Business Development, both reporting to SVP Paul Hadden. Their role will focus on sourcing and executing royalty financing opportunities. Additionally, Lauren Hay has been promoted to Vice President of Portfolio Strategy and Investments, overseeing the optimization and management of Ligand's existing portfolio assets.
Ligand Pharmaceuticals (LGND) director sells 1,000 shares, keeps stake
Ligand Pharmaceuticals director Stephen L. Sabba sold 1,000 shares of common stock on March 23, 2026, for an average price of $207.8727 per share. Following this transaction, Sabba directly holds 32,793 shares, which includes 1,209 restricted shares previously reported and expected to vest within six months. The sale was documented in a Form 4 SEC filing, indicating a net sale of approximately $208,000.
Clark Capital Management Group Inc. Acquires 11,858 Shares of Ligand Pharmaceuticals Incorporated $LGND
Clark Capital Management Group Inc. increased its stake in Ligand Pharmaceuticals Incorporated by 16.7% in the third quarter, purchasing an additional 11,858 shares. This acquisition brings their total holdings to 82,991 shares, valued at $14.7 million. Other institutional investors also significantly boosted their positions in Ligand Pharmaceuticals, while company insiders recently sold shares totaling millions.
LIGAND PHARMACEUTICALS CFO Sells Shares
LIGAND PHARMACEUTICALS' CFO, Espinoza Octavio, sold 3,057 shares of common stock for $687,825 on March 11, 2026. This transaction was part of a pre-arranged trading plan, leaving him with 21,010 direct shares in the company. The sale details were disclosed in an SEC Form 4 filing on March 13, 2026.
Russell Investments Group Ltd. Sells 9,403 Shares of Ligand Pharmaceuticals Incorporated $LGND
Russell Investments Group Ltd. has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 6.5% during the third quarter, selling 9,403 shares and now holding 136,130 shares valued at $24.1 million. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $245, following the company beating earnings expectations and providing strong FY2026 guidance. Institutional investors collectively own over 91% of Ligand Pharmaceuticals.
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating.
Bofa Global Research has initiated coverage of Ligand Pharmaceuticals Inc. with a "Buy" rating and set a target stock price of $244 for the biopharmaceutical company. The article cites this as new coverage for Ligand Pharmaceuticals.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and a $244 price target, highlighting the company's royalty-focused business model and diversified portfolio. Ligand's strategy of providing capital and technology to drug developers in exchange for royalties allows it to generate high-margin returns with reduced risk in the biopharma sector. The company's strong EPS growth, disciplined deal-making, and technology platforms like Captisol are key drivers for its projected 23% CAGR in royalty receipts through 2030.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, highlighting the company's royalty-focused business model and diversified portfolio. The firm believes Ligand's strategy of providing capital and technology in exchange for royalties allows it to deliver diversified, high-margin returns and continued EPS growth for investors seeking biopharma exposure with lower risk. The report also pointed to Ligand's strong investment team and its Captisol drug formulation technology as additional drivers for future growth and potential multiple expansion.
LIGAND PHARMACEUTICALS INC SEC 10-K Report
Ligand Pharmaceuticals Inc. has released its 2025 10-K report, highlighting significant financial growth with total revenue of $268.1 million and a net income of $124.5 million. The biopharmaceutical royalty aggregator operates with a lean model, focusing on acquiring and managing royalty interests in various biopharmaceutical products, including key assets like Kyprolis and Filspari. While demonstrating robust performance and strategic advancements like the Pelthos Transaction and new financing, the company also acknowledges operational, intellectual property, regulatory, and financial risks inherent in its business model.
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND
Vanguard Group Inc. decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 0.6% in the third quarter, yet still holds 10.59% of the company, valued at $367.79 million. Ligand Pharmaceuticals recently exceeded Q4 earnings and revenue expectations and provided strong FY2026 adjusted EPS guidance, projecting substantial growth in royalty revenue through 2030. Despite insider selling and some investor uncertainty regarding revenue guidance, analysts largely maintain a "Moderate Buy" rating for the stock.
Ligand Pharmaceuticals (NasdaqGM:LGND) Stock Price
This article provides an analysis of Ligand Pharmaceuticals (NasdaqGM:LGND), highlighting its stock performance, fair value, and financial metrics. It details the company's diverse royalty partnerships and asset-light acquisitions as key drivers for strengthening its global healthcare reach, boosting recurring revenue, and supporting future earnings. The report also includes recent news, key financial details, and comparisons with competitors.
